Navigation Links
Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
Date:9/20/2008

early departure from the workforce. Patients treated early with Betaseron fared better in tests of cognitive function compared to those with delayed treatment, which is good news for people with MS," Dr. Freedman said.

The BENEFIT study was the first to demonstrate a reduction in the risk of confirmed EDSS progression, as measured by the Expanded Disability Status Scale (EDSS), with early versus delayed treatment. This effect first appeared at year three, with a significant risk reduction of 40 percent (p=0.022).(2) Over five years, a nominal risk reduction of 24 percent (p=0.177) was observed for early treatment compared to delayed treatment. This difference over five years was not statistically significant.(1)

The key findings from the BENEFIT five-year study showed that:(1)

-- Starting Betaseron after the first clinical event delayed the development of CDMS by more than two years (750 days) in the 40th percentile.

-- Patients treated early with Betaseron had a greater reduction in relapse rate over five years compared to patients with delayed treatment, (0.21 versus 0.27) despite the latter receiving at least three years of treatment after the second attack or after two years (p=0.014; Poisson model). This effect was mainly due to the differences between the groups during the first two years.

-- Early treatment significantly reduced the development of newly active brain lesions (new or enlarging T2 lesions, Gd-enhancing lesions) compared to delayed treatment (p=0.0062).

-- In the BENEFIT study there was a high level of study completion of Betaseron by patients with the earliest signs of MS. Two-thirds of patients (67 percent) in the early treatment group continued on Betaseron for five years.

-- Patients consistently reported a high Health-Related Quality of Life over the five-year study period.

Adverse events (AEs) reported at five years were consistent with the product label.

About BENEFIT

B
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
5. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
6. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( www.syncardia.com ), ... Canada and CE ( Europe ) approved ... Centre in Scotland , which boasts ... SynCardia temporary Total Artificial Heart powered by the ... Bodyworks Exhibition, one of the most advanced exhibitions of ...
(Date:5/23/2013)... , May 23, 2013  PAREXEL International Corporation (NASDAQ: ... be presenting at the Jefferies Healthcare Conference in New ... President and Chief Financial Officer, will be making a ... p.m. ET on Monday, June 3, 2013. A ... the "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3PAREXEL International To Present At Jefferies Healthcare Conference 2
... Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today ... 23rd Annual Growth Stock Conference on Monday, March 14, 2011 ... in Dana Point, California and at the Barclays Capital 2011 ... a.m. ET at the Loews Miami Hotel, Florida. ...
... Inc. (Nasdaq: JAZZ ) today announced financial results for ... Total revenues for the fourth quarter of 2010 were ... 2009.  Full year 2010 revenues were $173.8 million, up 35 percent ... GAAP net income for the fourth quarter of 2010 was $24.5 ...
Cached Medicine Technology:Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results 2Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results 3Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results 4Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results 5Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results 6Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results 7Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results 8
(Date:5/23/2013)... 23, 2013 Elegance for a woman takes on ... her taste, her intrigue can often be found in the mystery ... a woman's soul is through her eyes. It is also ... is! That is why the elegance of a woman can be ... Women today, more than any other time, utilize eyewear to not ...
(Date:5/23/2013)... 2013 Aero Fulfillment Services, a national ... NewWave Biosciences to be the sole fulfillment provider for ... , Brad Cole, CEO New Wave Biosciences said, ... their central location, e-commerce experience with both of our ... end-to-end solution that will expand as our distribution grows.” ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 Each month ... most innovative and stylish eco-friendly hybrids and electric cars. Nowhere ... in Los Angeles, the symbolic green car capital. Thankfully this ... Car Tour ride and drive back to Dwell on ... event. , During the first two days of Dwell ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 Maintaining ... today launches its Summer Health Campaign. Kicking off in ... to offering a luxury bed for everyone and to ... overall health and well-being. , May is Better Sleep ... by the Better Sleep Council due to the Centers ...
(Date:5/23/2013)... two-thirds of patients with high-risk neuroblastoma a common tumor ... cured using tumor-killing cancer drugs. A study published by ... Chemistry & Biology reveals a new genomic approach ... by causing cancer cells to differentiate, or convert from ... screening method, the researchers identified a compound that causes ...
Breaking Medicine News(10 mins):Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2Health News:NewWave Biosciences Chooses Aero Fulfillment for e-Commerce Distribution of New Product to Reduce Inflammation 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5Health News:DUXIANA®, Quality Bed Innovator, Celebrates Better Sleep Month and Launches Summer Health Campaign 2Health News:New screening approach uncovers potential alternative drug therapies for neuroblastoma 2
... Jan. 8 A proposal by the State of ... Home has prompted the 125,000-member American Legion Department of ... 2009, in order to organize and coordinate its members, ... provides more than $50,000 in direct and in-kind support ...
... Jan. 8 United Jewish Communities (UJC) and the ... $10 million to address humanitarian and social needs in ... and stand in solidarity with Israelis during the current ... the Gaza Strip. The funds will enhance programs supported ...
... in French . -->, ... McGill University Health Centre (RI MUHC) and the McGill University ... Canadian and Belgian institutions, have discovered DNA variations in a ... was published in the January issue of the journal ...
... Nassau ColiseumNEW YORK, Jan. 8 Stand Up for a ... -- a Valentine,s Day show with Barry Manilow , in ... be held on February 14th, 2009 at Nassau Coliseum, and tickets ... Ticketmaster.com or by calling Stand Up for a Cure at 212 ...
... Many companies are starting out,the new year with ... than,ever will your success be dependent on your ... To excel in 2009 and win customers, hearts ... customer,listening posts, optimizing complaint management, applying savvy market,segmentation, ...
... We hear it everywhere: "What is your carbon footprint?" ... and how can you reduce yours? It isn,t all ... and planning to bring it down.Listen to this report from ... journalists can access video, audio, text, graphics and photos for ...
Cached Medicine News:Health News:UJC and Jewish Federations of North America Commit $10 Million for Needs in Southern Israel 2Health News:McGill researchers discover gene that increases susceptibility to Crohn's disease 2Health News:McGill researchers discover gene that increases susceptibility to Crohn's disease 3Health News:Barry Manilow Brings Valentine's and Music to New York With Concert to Raise Funds for Breast Cancer Research 2Health News:Marketers Share Customer-Centric Strategies for an Uncertain 2009 Economy, Feb 2-4 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: